|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RMDN2 |
Gene summary for RMDN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RMDN2 | Gene ID | 151393 |
| Gene name | regulator of microtubule dynamics 2 | |
| Gene Alias | BLOCK18 | |
| Cytomap | 2p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000922 | UniProtAcc | Q96LZ7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 151393 | RMDN2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.29e-16 | -5.96e-01 | 0.0155 |
| 151393 | RMDN2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.17e-08 | -5.84e-01 | -0.1808 |
| 151393 | RMDN2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.51e-06 | -5.98e-01 | -0.0811 |
| 151393 | RMDN2 | HTA11_78_2000001011 | Human | Colorectum | AD | 7.09e-04 | -4.79e-01 | -0.1088 |
| 151393 | RMDN2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.40e-05 | -5.62e-01 | -0.1207 |
| 151393 | RMDN2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.72e-19 | -5.26e-01 | -0.1464 |
| 151393 | RMDN2 | HTA11_866_2000001011 | Human | Colorectum | AD | 6.10e-20 | -5.48e-01 | -0.1001 |
| 151393 | RMDN2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.73e-09 | -5.47e-01 | -0.059 |
| 151393 | RMDN2 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.42e-02 | -5.38e-01 | -0.0842 |
| 151393 | RMDN2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.00e-02 | -5.82e-01 | -0.0179 |
| 151393 | RMDN2 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.40e-14 | -5.98e-01 | 0.096 |
| 151393 | RMDN2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.25e-06 | -5.71e-01 | 0.0338 |
| 151393 | RMDN2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.73e-23 | -5.72e-01 | 0.0674 |
| 151393 | RMDN2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.75e-05 | -5.83e-01 | 0.0588 |
| 151393 | RMDN2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.71e-27 | -5.93e-01 | 0.294 |
| 151393 | RMDN2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.95e-02 | -4.90e-01 | 0.281 |
| 151393 | RMDN2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.24e-18 | -5.40e-01 | 0.3859 |
| 151393 | RMDN2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.05e-05 | -6.08e-01 | 0.2585 |
| 151393 | RMDN2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.72e-28 | -6.02e-01 | 0.3005 |
| 151393 | RMDN2 | A002-C-010 | Human | Colorectum | FAP | 2.56e-05 | -3.38e-01 | 0.242 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RMDN2 | SNV | Missense_Mutation | novel | c.689N>A | p.Gly230Glu | p.G230E | protein_coding | tolerated_low_confidence(0.71) | benign(0.099) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RMDN2 | SNV | Missense_Mutation | c.62N>G | p.Asp21Gly | p.D21G | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.638) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| RMDN2 | SNV | Missense_Mutation | c.1240N>C | p.Glu414Gln | p.E414Q | protein_coding | deleterious(0.03) | probably_damaging(0.918) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | ||
| RMDN2 | insertion | Frame_Shift_Ins | novel | c.1599_1600insGATATTCCTAGGACAAGTCCTA | p.Tyr534AspfsTer10 | p.Y534Dfs*10 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | |||
| RMDN2 | SNV | Missense_Mutation | c.1279G>A | p.Glu427Lys | p.E427K | protein_coding | tolerated(0.13) | benign(0.444) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| RMDN2 | SNV | Missense_Mutation | novel | c.227N>A | p.Arg76Lys | p.R76K | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.488) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| RMDN2 | SNV | Missense_Mutation | c.959N>A | p.Ser320Tyr | p.S320Y | protein_coding | deleterious(0.01) | benign(0.413) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | ||
| RMDN2 | SNV | Missense_Mutation | rs776380587 | c.1245G>T | p.Lys415Asn | p.K415N | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| RMDN2 | SNV | Missense_Mutation | novel | c.293N>C | p.Glu98Ala | p.E98A | Q96LZ7 | protein_coding | tolerated(0.07) | possibly_damaging(0.88) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| RMDN2 | SNV | Missense_Mutation | novel | c.556N>C | p.Asn186His | p.N186H | protein_coding | tolerated_low_confidence(1) | benign(0.006) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |